Email
Print
Ankylosing Spondylitis Market by Drug Class (NSAIDs, TNF Inhibitors and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Forecast(2024 - 2030)
Ankylosing Spondylitis Market Overview:
Ankylosing Spondylitis Market size is estimated to reach $ 5500 Million by 2030, growing at a CAGR of 8.2 % during the forecast period 2023-2030.During the forecast period, it is anticipated that advancements in automation for bullet loading, Ankylosing Spondylitis (AS) is a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints. It can also affect other joints in the body, such as the hips, shoulders, and knees. AS is a chronic condition that can lead to stiffness and limited mobility in the affected joints.
Market Snapshot:
Ankylosing Spondylitis Market - Report Coverage:
The “Ankylosing Spondylitis Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Ankylosing Spondylitis Market.
| Attribute | Segment |
|---|---|
By Drug Class |
|
By Distribution Channel |
|
By Disease Stage |
|
By Geography |
|
Ankylosing Spondylitis Report – Top Trends
Use of Biologics: Biologic medications are changing the landscape of Ankylosing Spondylitis treatment. They target the inflammation causing the disease and can help reduce pain and inflammation in the joints. This has led to improved outcomes and quality of life for patients.
Early Diagnosis: Earlier diagnosis of Ankylosing Spondylitis is crucial as early treatment can help prevent joint damage and improve long-term outcomes. Advances in diagnostic imaging and testing have made early detection easier.
Patient Education: Patient education is a critical aspect of managing Ankylosing Spondylitis. This includes educating patients on self-care strategies, such as exercise and posture, and medication adherence. Patients who are actively involved in managing their condition tend to have better outcomes.
Alternatives to Biologics: While biologics have been a game-changer in Ankylosing Spondylitis treatment, they can be expensive. Researchers are investigating alternative treatments, such as stem cell therapy and gene therapy, which could be more cost-effective.
More Comprehensive Care: Ankylosing Spondylitis requires a comprehensive approach to care, including management of co-morbidities (such as uveitis and inflammatory bowel disease) and support for mental health and well-being. Clinicians are recognizing the importance of a multidisciplinary approach to care.
Ankylosing Spondylitis - Company Product Analysis
Product Pipeline: Companies are investing in the research and development of new products for Ankylosing Spondylitis treatment. Several drugs are currently in clinical trials and have shown promising results so far.
Market Competition: With the emergence of biologics in Ankylosing Spondylitis treatment, there has been increased market competition among pharmaceutical companies. Companies are trying to develop novel and more effective biologics to gain a competitive edge.
Product Launches: There have been recent product launches in the Ankylosing Spondylitis market, such as biosimilars and oral medications. These launches are expected to increase revenue for the companies and provide patients with more treatment options.
Pricing Strategies: Biologic medications for Ankylosing Spondylitis can be expensive, and companies are adopting different pricing strategies to make their products more accessible. This includes offering discounts and rebates to patients and negotiating with insurance providers.
Marketing Initiatives: Companies are investing in marketing initiatives to increase awareness about their products and target healthcare professionals. This includes organizing educational events and providing online resources for patients and physicians.
Patient Support Programs: Companies are also launching patient support programs to provide assistance and resources to Ankylosing Spondylitis patients. These programs include financial assistance, nurse support, and educational materials to help patients manage their condition.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Market. The top 10 companies in Ankylosing Spondylitis industry are listed below:
- Pfizer
- Eli Lilly
- Sanofi
- AstraZeneca
- Biogen Idec
- Boehringer Ingelheim
- Teva Pharmaceutical
- Bayer
- Roche
- Takeda Pharmaceuticals
Scope of Report:
| Report Metric | Details |
|---|---|
Base Year Considered | 2023 |
Forecast Period | 2023–2030 |
CAGR | 8.2 % |
Market Size in 2030 | $ 10,500 Million |
Segments Covered | By Drug Class, By Distribution Channel, By REGION, By Geography |
Geographies Covered | North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa). |
Key Market Players |
|
For more Food and Beverage Market reports, please click here
1. Ankylosing Spondylitis Market- Overview
1.1. Definitions and Scope
2. Ankylosing Spondylitis Market- Executive Summary
3. Ankylosing Spondylitis Market- Comparative Analysis
3.1. Company Benchmarking - Key Companies
3.2. Global Financial Analysis - Key Companies
3.3. Market Share Analysis - Key Companies
3.4. Patent Analysis
3.5. Pricing Analysis
4. Ankylosing Spondylitis Market- Start-up Companies Scenario (Premium)
4.1. Key Start-up Company Analysis by
4.2. Investment
4.3. Revenue
4.4. Venture Capital and Funding Scenario
5. Ankylosing Spondylitis Market– Market Entry Scenario Premium (Premium)
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing Business Index
5.3. Case Studies of Successful Ventures
6. Ankylosing Spondylitis Market- Forces
6.1. Market Drivers
6.2. Market Constraints
6.3. Market Challenges
6.4. Porter's Five Force Model
6.5. Bargaining Power of Suppliers
6.6. Bargaining Powers of Customers
6.7. Threat of New Entrants
6.8. Rivalry Among Existing Players
6.9. Threat of Substitutes
7. Ankylosing Spondylitis Market– Strategic Analysis
7.1. Value Chain Analysis
7.2. Opportunities Analysis
7.3. Market Life Cycle
8. Ankylosing Spondylitis Market– By Drug Class (Market Size – $Million/$Billion)
8.1. NSAIDs
8.1.1 Key Market Trends, Growth Factors and Opportunities
8.1.2 Market Size & Forecast by Region
8.2 TNF inhibitors
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Market Size & Forecast by Region
8.3 others
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Market Size & Forecast by Region
9. Ankylosing Spondylitis Market– By Distribution Channel (Market Size – $Million/$Billion)
9.1. Hospital pharmacy
9.1.1 Key Market Trends, Growth Factors and Opportunities
9.1.2 Market Size & Forecast by Region
9.2. Retail pharmacy
9.2.1 Key Market Trends, Growth Factors and Opportunities
9.2.2 Market Size & Forecast by Region
9.3. Online pharmacy
9.3.1 Key Market Trends, Growth Factors and Opportunities
9.3.2 Market Size & Forecast by Region
10. Ankylosing Spondylitis Market– By Disease Stage (Market Size – $Million/$Billion)
10.1. Early disease stage
10.1.1 Key Market Trends, Growth Factors and Opportunities
10.1.2 Market Size & Forecast by Region
10.2. Moderate disease stage
10.2.1 Key Market Trends, Growth Factors and Opportunities
10.2.2 Market Size & Forecast by Region
10.3. Severe disease stage
10.3.1 Key Market Trends, Growth Factors and Opportunities
10.3.2 Market Size & Forecast by Region
11. Ankylosing Spondylitis Market– by End-Use (Market Size – $Million/$Billion)
11.1. Residential
11.1.1 Key Market Trends, Growth Factors and Opportunities
11.1.2 Market Size & Forecast by Region
11.2. Non-Residential (Commercial/Industrial)
11.2.1 Key Market Trends, Growth Factors and Opportunities
11.2.2 Market Size & Forecast by Region
12. Ankylosing Spondylitis Market– by Geography (Market Size – $Million/$Billion)
12.1. North America
12.1.1. The U.S.
12.1.2. Canada
12.1.3. Mexico
12.2. Europe
12.2.1. UK
12.2.2. Germany
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Russia
12.2.7.Rest of Europe
12.3. Asia-Pacific
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. South Korea
12.3.5. Australia & New Zealand
12.3.6. Rest of Asia-Pacific
12.4. South America
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Chile
12.4.4. Colombia
12.4.5. Rest of South America
12.5. Rest of the World
12.5.1. Middle East
12.5.2. Africa
13. Ankylosing Spondylitis Market– Entropy
14. Ankylosing Spondylitis Market– Industry/Segment Competition Landscape Premium
14.1. Market Share Analysis
14.1.1. Market Share by Product Type – Key Companies
14.1.2. Market Share by Region – Key Companies
14.1.3. Market Share by Country – Key Companies
14.2. Competition Matrix
14.3. Best Practices for Companies
15. Ankylosing Spondylitis Market– Key Company List by Country Premium Premium
16. Ankylosing Spondylitis Market- Company Analysis
16.1. Novartis
16.2. Johnson & Johnson
16.3. Pfizer
16.4. AbbVie
16.5. Amgen
16.6. Bristol-Myers Squibb
16.7. Celgene
16.8. Merck
16.9. UCB
16.10. GlaxoSmithKline
16.11. Pfizer,
16.12. Eli Lilly
16.13. Sanofi
16.14. AstraZeneca
16.15. Biogen Idec
16.16. Boehringer Ingelheim
16.17. Teva Pharmaceutical
16.18. Bayer
16.19. Roche
16.20. Takeda Pharmaceuticals
"Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our
reports include global-level data, niche markets and competitive landscape.
The Ankylosing Spondylitis Market is projected to grow at 8.2 % CAGR during the forecast period 2023-2030.
Global Ankylosing Spondylitis Market size is estimated to reach $ 10,500 Million by 2030.
The leading players in the Ankylosing Spondylitis Market are Novartis AG, AbbVie Inc, Amgen Inc, Boehringer Ingelheim International GmbH, UCB S.A. and others.